Torres-Arenas E, Gámez-Lares RM, Rojo-Quiñonez AR

Language: Spanish
References: 12
Page: 134-137
PDF size: 252.96 Kb.

ABSTRACT

Introduction: Autoimmune hemolytic anemia is defined by destruction of erythrocytes by antibodies to membrane antigens themselves. According to the characteristics of the antibody involved can be for hot, cold or mixed antibodies; depending on the temperature at which the antibodies are activated. In Mexico an estimated 1,311 cases per year is estimated.
Clinical Case: For women aged 19 to 31.4 weeks by ultrasound pregnancy with autoimmune hemolytic anemia cold antibody is reported, torpid evolution presents transfusion of blood and appearance of herpes lesions, withslow response tosteroids and immunoglobulins, achieving favorable outcomefor binomial maternal fetal.
Conclusion: The diagnosis of autoimmune hemolytic anemia is challenging due to their low incidence. The prognosis depends on the underlying cause disease and that adequate and timely handling of symptoms takes place, but the disease is usually not fatal.

REFERENCES

1. 1.- Ruiz AG.Fundamentos de hematología. 4ª ed México. Editorial Médica Panamericana S.A de C.V. 2009 p. 107.

2. 2.- Guía de práctica clínica CENETEC IMSS-389-10. Diagnóstico y tratamiento de anemia hemolítica autoinmune.

3. 3.- Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;16:1831–8.

4. 4.- Vanamala A. et. Cols. Clinical patterns and hematological spectrum in autoinmune hemolytic anemia. Journal of Laboratory Physicians. 2010; 2:17-20.

5. 5.- Wendell, F. et al. “inmune mediated hemolytic anemia”. Hematology educational Book. ASH 2004.

6. 6.- Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013; 91: 546–51.

7. 7.- Maryann M. B., et. Cols. Clinical and hematological characteristics of autoimmune haemolytic anemia: retrospective analysis of 10 cases. Pacifice Group of e-Jornals. 2015. A-47 a A-50.

8. 8.- Berensten S. Complement, cold agglutinins, and therapy. Blood 2014: 123: 4010.

9. 9.- Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010; 116: 4783–5.

10. 10.- Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood. 2012;119:3691–7.

11. 11.- Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J MedAssoc Thai. 2010;93(Suppl 1): S165–S170.

12. 12.- Pérez JC, Rodriguez MM, Gomez-de-Léon A, Arzaga LT, Gomez A. D.Current approaches for the treatment of autoimmune hemolytic anemia. ArchImmunolTherExp. 2013; 61: 385–95.